Document is current
Any future updates will be listed below
-
Authors
Lyu, Aram https://orcid.org/0000-0003-3044-4887
Fan, Zenghua
Clark, Matthew
Lea, Averey
Luong, Diamond
Setayesh, Ali
Starzinski, Alec
Wolters, Rachel
Arias-Badia, Marcel https://orcid.org/0000-0003-2270-0676
Allaire, Kate
Wu, Kai
Gurunathan, Vibha
Valderrábano, Laura
Wei, Xiao X.
Miller, Richard A. https://orcid.org/0000-0002-5696-2503
Van Allen, Eliezer M. https://orcid.org/0000-0002-0201-4444
Fong, Lawrence https://orcid.org/0000-0002-6428-428X
- License Information
-
More Information
Article History
Received: 19 January 2024
Accepted: 25 October 2024
First Online: 4 December 2024
Competing interests
: L.F. has received research support from Roche/Genentech, Abbvie, Bavarian Nordic, Bristol Myers Squibb, Dendreon, Janssen and Merck; has served on the scientific advisory boards of Actym, Astra Zeneca, Bioatla, Bristol Myers Squibb, Daiichi Sankyo, Immunogenesis, Innovent, Merck, Merck KGA, Nutcracker, RAPT, Senti, Sutro and Roche/Genentech; and reports ownership interest in Actym, BioAtla, ImmunoGenesis, Nutcracker, RAPT, Senti and Therapaint. R.A.M. is an employee of Corvus Pharmaceuticals. E.M.V.A. has received research support from Novartis, BMS and Sanofi, and served on the scientific advisory boards of Tango Therapeutics, Genome Medical, Genomic Life, Enara Bio, Manifold Bio, Monte Rosa, Novartis Institute for Biomedical Research, Riva Therapeutics and Serinus Bio. The remaining authors declare no competing interests.
